Newest studies

Multidimensional MRI reveals cortical astrogliosis linked to dementia in Alzheimer’s disease

43/100 ✓ Peer-reviewed Getting a diagnosis Brain Communications

Key finding: Finally, we showed that the MD-MRI-derived astrogliosis biomarker is the only MRI measure capable of predicting cognitive state. +4 more findings

• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Normative data of the Spanish version of the Montreal Cognitive Assessment (MoCA) in older individuals from Peru

34/100 ✓ Peer-reviewed Getting a diagnosis Dementia & Neuropsychologia

Key finding: Sex was not a predictor of the total scores of MoCA. +3 more findings

• Diagnosis

Full summary, score breakdown and related studies → Original source

Focus groups on digital cognitive assessment in the context of Alzheimer's disease

44/100 ✓ Peer-reviewed Getting a diagnosis Digital Health

Key finding: Participants recognized the added value of DCAs, and multiple factors were identified as facilitators and barriers for their use.

• Diagnosis
• Digital Tools

Full summary, score breakdown and related studies → Original source

Diagnosis of Alzheimer’s Disease and Frontotemporal Dementia From Electroencephalography Signals

40/100 ✓ Peer-reviewed Getting a diagnosis IEEE Transactions on Neural Systems and Rehabilitation Engineering

Key finding: Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most burdensome neurodegenerative disorders in older populations as they pose significant challenges because of subtle cognitive decline in the initial stages. +3 more findings

• Diagnosis
• Other Dementias

Full summary, score breakdown and related studies → Original source

Clinical Utility and Diagnostic Accuracy of the Tablet-Based Seoul Cognitive Status Test: Evidence for Scalable Cognitive Assessment

43/100 ✓ Peer-reviewed Getting a diagnosis Dementia and Neurocognitive Disorders

Key finding: <0.001), with key domain correlations ≥0.7 (language, memory, executive). +4 more findings

• Diagnosis
• Early Stage

Full summary, score breakdown and related studies → Original source

Diversity of complementary diet and early food allergy risk

49/100 ✓ Peer-reviewed Prevention and risk Pediatric Allergy and Immunology

Key finding: High weighted DD scores (24-31p) at age 9 months were associated with 61% decreased odds of FA at age 18 months [OR (95% CI) = 0.39 0.18-0.88] compared with infants with the lowest DD scores (0-17p). +4 more findings

• Lifestyle

Full summary, score breakdown and related studies → Original source

Factors of Vulnerability and Resilience of Persons with Disabilities During Disasters: Challenges and Strategies for Inclusive Risk Reduction

37/100 ✓ Peer-reviewed Prevention and risk International Journal of Disaster Risk Management

Key finding: Persons with disabilities (PWDs) are among the most at-risk groups during disaster situations due to various physical, sensory, cognitive, and systemic challenges that hinder their ability to prepare for, respond to, and recover from crises.

• Prevention

Full summary, score breakdown and related studies → Original source

Cardiovascular Disease Management and Prevention in Saudi Arabia: Strategies, Risk Factors, and Targeted Interventions

38/100 ✓ Peer-reviewed Prevention and risk International Journal of Clinical Practice

Key finding: It reviews the epidemiology of CVDs in the Kingdom of Saudi Arabia, outlining some of the major risk factors and also their impact on public health. +4 more findings

• Risk Factors
• Prevention
• Policy

Full summary, score breakdown and related studies → Original source

Running‐Centred Injury Prevention Support: A Scoping Review on Current Injury Risk Reduction Practices for Runners

42/100 ✓ Peer-reviewed Prevention and risk Translational Sports Medicine

Key finding: A total of 3777 studies were identified, and 106 studies met the inclusion criteria. +4 more findings

• Prevention

Full summary, score breakdown and related studies → Original source

Early detection and management of hearing loss to reduce dementia risk in older adults with mild cognitive impairment: findings from the treating auditory impairment and cognition trial (TACT)

66/100 ✓ Peer-reviewed Prevention and risk Age and Ageing

Key finding: From October 2018 to March 2020, 58 participants were recruited (29 per group, 95% [86%-99%]). +4 more findings

• Clinical Trials
• Risk Factors
• Early Stage

Full summary, score breakdown and related studies → Original source

A review of disaster risk reduction education implementation: Integration, trends, and trajectories

36/100 ✓ Peer-reviewed Prevention and risk Social Sciences & Humanities Open

Key finding: Although progress in policymaking and curriculum integration is evident, significant practical and strategic barriers remain.

• Prevention

Full summary, score breakdown and related studies → Original source

Cancer statistics in China: Epidemiology, risk factors, and prevention

44/100 ✓ Peer-reviewed Prevention and risk Chinese Journal of Cancer Research

Key finding: China has made measurable progress in cancer control. +4 more findings

• Prevention
• Risk Factors
• Policy

Full summary, score breakdown and related studies → Original source

Pharmaceutical developments in alzheimer's disease: An emphasis on blarcamesine

27/100 ✓ Peer-reviewed Treatments International Journal of Pharmacology and Clinical Research

Key finding: Recent developments have led to a significant increase in the global prevalence of dementia, with estimates suggesting that up to 150 million people will be affected by the condition by 2050.However exposure to head trauma, infections, and environmental factors also plays a role in promoting the development of the Alzheimer's disease The progression Alzheimer's diseasei of occurs in three phases, mild, moderate and severe with the ultimate outcome being complete dependence on caregivers.

• Treatments
• Brain Biology

Full summary, score breakdown and related studies → Original source

A Novel Mouse Model for Investigating ARIAs in Response to Anti-Abeta Immunotherapy

28/100 ✓ Peer-reviewed Treatments Cerebral Circulation - Cognition and Behavior

Key finding: Study 1 was designed for 8 weeks with weekly 3D6.IgG2a injections, but was aborted after the first injection when 7/10 mice died within 36 hours. +4 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes

27/100 ✓ Peer-reviewed Treatments JuSER Publikationsportal

Key finding: However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease. +2 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Nieuwe geneesmiddelen bij Alzheimer - Update

27/100 ✓ Peer-reviewed Treatments Geneesmiddelenbulletin

Key finding: Met de registratie van lecanemab in april 2025 en donanemab in september 2025 komt slechts voor een klein deel van de patiënten in het beginstadium van de ziekte van Alzheimer een mogelijke therapie binnen bereik. +1 more finding

Full summary, score breakdown and related studies → Original source

The Cost of Alzheimer Drug Treatment

27/100 ✓ Peer-reviewed Treatments Medical Research Archives

Key finding: Pembrolizumab was $160,00, durvalumab $115,000, Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000. +3 more findings

• Treatments
• Policy

Full summary, score breakdown and related studies → Original source

Therapierefraktärer Status epilepticus bei Therapie mit Anti-Amyloid-AK

25/100 ✓ Peer-reviewed Treatments Neuroradiologie Scan

Key finding: Fazit Bei der Behandlung eines Morbus Alzheimer sollten sich Kliniker immer ins Gedächtnis rufen, dass spezifisch gegen die Alzheimer-typischen Veränderungen gerichtete Therapien mit schweren Nebenwirkungen einher gehen können, so die Autoren. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions

51/100 ✓ Peer-reviewed Treatments Alzheimer s & Dementia

Key finding: This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging.

• Treatments
• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source

Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer

27/100 ✓ Peer-reviewed Treatments Acta Médica Grupo Ángeles

Key finding: Introducción: la enfermedad de Alzheimer (EA) se define como un trastorno neurodegenerativo caracterizado por acumulación de placas beta amiloide a nivel cerebral, lo cual ocasiona alteraciones histopatológicas y se manifiesta, principalmente, en el deterioro cognitivo (DC).Objetivo: evaluar el efecto de lecanemab sobre el DC en pacientes con EA.Material y métodos: metaanálisis de artículos originales que evaluaron el DC durante los periodos de intervención con placebo y lecanemab.

• Treatments

Full summary, score breakdown and related studies → Original source

Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease

51/100 ✓ Peer-reviewed Treatments Alzheimer s & Dementia Translational Research & Clinical Interventions

Key finding: A total of 282 participants were followed for an average of 2.9 years (standard deviation [SD] 1.3 years). +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

The causal association between resting state intrinsic functional networks and neurodegeneration

43/100 ✓ Peer-reviewed Genetics Brain Communications

Key finding: None of the genetically proxied functional network features were significantly associated with neurodegenerative outcomes (adjusted P value >0.05), despite sufficient calculated power. +4 more findings

Full summary, score breakdown and related studies → Original source

Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer’s disease

41/100 ✓ Peer-reviewed Genetics Brain Communications

Key finding: We observed differential cellular effects on β-amyloid, pTau217 and cognitive measures. +2 more findings

• Genetics
• Biomarkers

Full summary, score breakdown and related studies → Original source

Blutbiomarker für Morbus Alzheimer

26/100 ✓ Peer-reviewed Biomarkers DMW - Deutsche Medizinische Wochenschrift

Key finding: Extrazelluläre β-Amyloid-Ablagerungen und intrazellulär angereichertes Tau-Protein sind Schlüsselelemente in der Pathophysiologie. +4 more findings

Full summary, score breakdown and related studies → Original source

Interplay between Alzheimer and vascular pathology as determinants of plasma neurofilament light in a memory clinic population

41/100 ✓ Peer-reviewed Biomarkers Cerebral Circulation - Cognition and Behavior

Key finding: Vascular burden influences NfL levels, particularly in A- individuals at a symptomatic stage. +4 more findings

• Biomarkers
• Early Stage
• Care Services

Full summary, score breakdown and related studies → Original source